ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.869T>A (p.Leu290Ter)

dbSNP: rs730881468
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000410713 SCV000489381 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2016-09-27 criteria provided, single submitter clinical testing
Invitae RCV001039562 SCV001203094 pathogenic Hereditary breast ovarian cancer syndrome 2024-01-30 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Leu290*) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 371981). For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001039562 SCV001364037 pathogenic Hereditary breast ovarian cancer syndrome 2019-10-29 criteria provided, single submitter clinical testing Variant summary: BRCA1 c.869T>A (p.Leu290X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251130 control chromosomes (gnomAD). To our knowledge, no occurrence of c.869T>A in individuals affected with Hereditary Breast and Ovarian Cancer and no experimental evidence demonstrating its impact on protein function have been reported. However, another variant at this position, c.869T>G, likewise resulting in truncation of the BRCA1 protein (p.Leu290X), has been observed in individuals affected with Hereditary Breast and Ovarian Cancer (e.g. PMID: 26681312, PMID: 29446198) and has been cited as pathogenic in ClinVar (reviewed by expert panel, ENIGMA). A ClinVar submitter (evaluation after 2014) cites the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Ambry Genetics RCV002374614 SCV002684131 pathogenic Hereditary cancer-predisposing syndrome 2016-12-13 criteria provided, single submitter clinical testing The p.L290* pathogenic mutation (also known as c.869T>A), located in coding exon 9 of the BRCA1 gene, results from a T to A substitution at nucleotide position 869. This changes the amino acid from a leucine to a stop codon within coding exon 9. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Baylor Genetics RCV000410713 SCV004212763 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2023-09-14 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.